• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Can-Fite Biopharma Ltd Sponsored ADR (Israel)

    6/23/25 4:15:13 PM ET
    $CANF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CANF alert in real time by email
    6-K 1 ea0246482-6k_canfite.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    Report of Foreign Private Issuer

    Pursuant to Rule 13a-16 or 15d-16

    Under the Securities Exchange Act of 1934

     

    For the Month of June 2025

     

    001-36203

    (Commission File Number)

     

    CAN-FITE BIOPHARMA LTD.

    (Exact name of Registrant as specified in its charter)

     

    26 Ben Gurion Street

    Ramat Gan 5257346 Israel

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒           Form 40-F ☐

     

     

     

     

     

    On June 23, 2025, Can-Fite BioPharma Ltd. (the “Company”) convened the Annual General Meeting of Shareholders (the “Annual General Meeting”), however, the Annual General Meeting was adjourned for one week to the same day, time and place due to lack of quorum. Accordingly, the Company’s Annual General Meeting will be reconvened on Monday, June 30, 2025 at 3:00 p.m., Israel time at the Company’s offices located at 26 Ben Gurion Street, Ramat Gan, Israel.

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Date: June 23, 2025 By: /s/ Motti Farbstein
        Motti Farbstein
        Chief Executive Officer and Chief Financial Officer

     

     

    2

     

    Get the next $CANF alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CANF

    DatePrice TargetRatingAnalyst
    6/24/2021$5.00Buy
    Aegis Capital
    More analyst ratings